Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 5/2024

07-03-2024 | Benign Prostatic Hypertrophy

Medical Advancements in Benign Prostatic Hyperplasia Treatments

Authors: Vishnuvardhan Ganesan, Deepak Agarwal

Published in: Current Urology Reports | Issue 5/2024

Login to get access

Abstract

Purpose of Review

This review aims to identify and summarize the current literature on the most recent therapeutic agents and combination strategies for the medical management of lower urinary tract symptoms resulting from benign prostatic hyperplasia.

Recent Findings

The latest advancements in BPH therapy have been in combination strategies. Alpha blockers continue to be the mainstay of treatment, but research is exploring the synergistic benefits of combining them with 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and beta-3 agonists.

Summary

The alpha-blocker + 5-ARI combination remains ideal for enlarged, significantly reducing clinical progression risk compared to monotherapy. Alpha-blocker + PDE5 inhibitor combinations appear safe and potentially beneficial for men with concomitant erectile dysfunction; sildenafil might hold an edge over tadalafil based on limited data. Beta-3 agonists show synergistic effects with alpha blockers for residual storage symptoms, offering similar efficacy to anticholinergics but with a better side effect profile.
Literature
1.
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–97.PubMedCrossRef
2.
Welliver C, Feinstein L, Ward JB, Fwu C-W, Kirkali Z, Bavendam T, et al. Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. J Urol. 2020;203:171–8.PubMedCrossRef
3.
Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255–63.PubMed
4.
5.
Yuan J-Q, Mao C, Wong SY-S, Yang Z-Y, Fu X-H, Dai X-Y, et al. Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore). 2015;94:e974.
6.
Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis. Low Urin Tract Symptoms. 2018;10:84–92.PubMedCrossRef
7.
Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2013;189:S135-140.PubMedCrossRef
8.
McVary KT, Monnig W, Camps JL, Young JM, Tseng L-J, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071–7.PubMedCrossRef
9.
Zahir M, Samzadeh M, Poopak A, Khoshdel AR, Armin A. Sildenafil vs. tadalafil for the treatment of benign prostatic hyperplasia: a single-arm self-controlled clinical trial. Urol J. 2023;20:255–60.
10.
Zhu Y-S, Imperato-McGinley JL. 5Alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009;1155:43–56.PubMedCrossRef
11.
Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG. 5-Alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl Urol. 2023;12:487–96.PubMedPubMedCentralCrossRef
12.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557–63.
13.
Li Y, Ma J, Qin X-H, Hu C-Y. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol. 2022;11:313–24.PubMedPubMedCentralCrossRef
14.
Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130–48.PubMedCrossRef
15.
• Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179:1084–93. Relevant recent paper showing association between anticholinergic drugs and risk of dementia in older adults.
16.
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361: k1315.PubMedPubMedCentralCrossRef
17.
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–63.PubMedCrossRef
18.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–28.PubMedCrossRef
19.
Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int. 2008;102:1133–9.PubMedCrossRef
20.
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324–33.PubMedCrossRef
21.
Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the - adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190:1320–7.PubMedCrossRef
22.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.PubMedCrossRef
23.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616–21.PubMedCrossRef
24.
Yamanishi T, Asakura H, Seki N, Tokunaga S. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). Low Urin Tract Symptoms. 2019;11:115–21.PubMedCrossRef
25.
Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191:727–33.PubMedCrossRef
26.
Roehrborn CG, Casabé A, Glina S, Sorsaburu S, Henneges C, Viktrup L. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int J Urol Off J Jpn Urol Assoc. 2015;22:582–7.
27.
Goldfischer E, Kowalczyk JJ, Clark WR, Brady E, Shane MA, Dgetluck N, et al. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. Urology. 2012;79:875–82.PubMedCrossRef
28.
Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, et al. Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. J Sex Med. 2017;14:1018–27.PubMedCrossRef
29.
• AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022;40:2063–70. Relevant paper that shows the benefit of combination therapy of alpha blockers and PDE5 inhibitors.
30.
Singh I, Tk A, Gupta S. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. Int J Clin Pract. 2020;74: e13530.PubMedCrossRef
31.
Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, et al. Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial. Arab J Urol. 2017;15:53–9.PubMedCrossRef
32.
Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64:398–407.PubMedCrossRef
33.
Pang R, Zhou X-Y, Wang X, Wang B, Yin X-L, Bo H, et al. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. Cochrane Database Syst Rev. 2021;2:CD012336.
34.
Kakizaki H, Lee K-S, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2020;6:729–37.PubMedCrossRef
35.
Matsukawa Y, Takai S, Majima T, Funahashi Y, Sassa N, Kato M, et al. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn. 2019;38:941–9.PubMedCrossRef
36.
• Elbaz R, El-Assmy A, Zahran MH, Hashem A, Shokeir AA. Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: a randomized controlled trial. Int J Urol Off J Jpn Urol Assoc. 2022;29:390–6. Relevant paper showing that Beta-3 agonists in combination with apha blockers are safe and show similar efficacy as anticholinergics.
37.
Soliman MG, El-Abd SA, Tawfik AM, Radwan MH, El-Abd AS. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol. 2021;39:2049–54.PubMedCrossRef
38.
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12:CD001423.
39.
Lee CL, Shin H-K, Lee JY, Kwon O, Seo C-S, Kim A-R, et al. Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: a double-blinded, randomized, pilot clinical trial. Int J Urol Off J Jpn Urol Assoc. 2022;29:503–9.
40.
Leibbrand M, Siefer S, Schön C, Perrinjaquet-Moccetti T, Kompek A, Csernich A, et al. Effects of an oil-free hydroethanolic pumpkin seed extract on symptom frequency and severity in men with benign prostatic hyperplasia: a pilot study in humans. J Med Food. 2019;22:551–9.PubMedPubMedCentralCrossRef
41.
Zerafatjou N, Amirzargar M, Biglarkhani M, Shobeirian F, Zoghi G. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial. BMC Urol. 2021;21:147.PubMedPubMedCentralCrossRef
42.
Fotovat A, Samadzadeh B, Ayati M, Nowroozi MR, Momeni SA, Yavari S, et al. The effect of melatonin on improving the benign prostatic hyperplasia urinary symptoms, a randomized clinical trial. Urol J. 2022;19:406–11.PubMed
43.
Karami AA, Zameni H, Salehi M, Mirhashemi SM. The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial. World J Urol. 2023;41:2465–71.PubMedCrossRef
44.
Perumal C, Chowdhury PS, Ananthakrishnan N, Nayak P, Gurumurthy S. A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urol Ann. 2015;7:74–8.PubMedPubMedCentralCrossRef
45.
Ückert S, Kedia GT, Tsikas D, Simon A, Bannowsky A, Kuczyk MA. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World J Urol. 2020;38:1423–35.PubMedCrossRef
46.
Roehrborn CG. The development of lonidamine for benign prostatic hyperplasia and other indications. Rev Urol. 2005;7(Suppl 7):S12-20.PubMedPubMedCentral
47.
Debruyne F, Tzvetkov M, Altarac S, Geavlete PA. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology. 2010;76:927–33.PubMedCrossRef
48.
Park HK, Choo GY, Chung H, Paick SH, Kim HG, Kim HS, et al. Effect of intravesical prostatic protrusion on the characteristics of lower urinary tract symptom change after 12-week drug medication: a prospective analysis. Low Urin Tract Symptoms. 2013;5:1–4.PubMedCrossRef
49.
Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA. Prostate transition zone fibrosis is associated with clinical progression in the MTOPS study. J Urol. 2019;202:1240–7.PubMedPubMedCentralCrossRef
Metadata
Title
Medical Advancements in Benign Prostatic Hyperplasia Treatments
Authors
Vishnuvardhan Ganesan
Deepak Agarwal
Publication date
07-03-2024
Publisher
Springer US
Published in
Current Urology Reports / Issue 5/2024
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-024-01199-4